Communiqués Personalis, Inc.

Actions

PSNL

US71535D1063

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 11/08/2026			Varia. 5j.	Varia. 1 janv.
14,02 ^USD	-3,31%		+6,21%	+76,13%

04/08	Flash résultats (PSNL) : Personalis, Inc. publie un chiffre d'affaires de 22,4 millions de dollars au deuxième trimestre, contre 16,7 millions de dollars attendus par le consensus FactSet	MT
04/08	Personalis, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

05/08	Personalis : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
04/08	Personalis: Q2 Earnings Snapshot	AQ
04/08	Personalis Reports Second Quarter Results and Recent Highlights	BU
04/08	PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI	AQ
22/07	Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL	BU
20/07	PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders	BU
20/07	Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform	BU
14/07	Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain	BU
09/06	Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits	BU
02/06	Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026	BU
26/05	Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium	BU
20/05	Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring	BU
14/05	Personalis to Participate in Upcoming Investor Events	BU
13/05	Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors	BU
08/05	Personalis : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Personalis: Q1 Earnings Snapshot	AQ
07/05	Personalis Reports First Quarter Results and Recent Highlights	BU
23/04	Personalis to Announce First Quarter 2026 Financial Results	BU
21/04	Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026	BU
13/04	Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026	BU
01/04	Personalis to Participate in the 25th Annual Needham Virtual Conference	BU
17/03	Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption	BU
12/03	Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®	BU
26/02	Personalis: Q4 Earnings Snapshot	AQ
26/02	Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights	BU